Decreased expression of the GLP-1 receptor after segmental artery injury in mice
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide-1 receptor (GLP1R) is expressed in the renal vasculature and known to be downregulated under hypertensive conditions in rats and humans. However, little is known about the regulation in other types of renal pathology involving vascular changes. This study investigates the expression of the GLP1R in renal vasculature after glomerular injury in the nephrotoxic nephritis mouse model, high cholesterol, and atherosclerosis in the Ldlr-/- mouse on Western diet, and ex vivo injury in an organ culture model. The immunohistochemical signal of the GLP1R was significantly decreased in arteries from mice with nephrotoxic nephritis after 42 days compared to 7 days and saline control ( P < 0.05). Histological evaluation of kidneys from Ldlr-/- mice on Western diet showed a decreased GLP1R specific immunohistochemical signal ( P < 0.05). The dilatory response to liraglutide was decreased in Western diet fed Ldlr-/- mice compared to C57Bl/6J controls ( P < 0.05). Organ culture significantly decreased the immunohistochemical signal of the GLP1R ( P <0.05) and the expression of Glp1r mRNA ( P < 0.005) compared to fresh. Organ cultured vessels showed vascular smooth muscle cell remodelling as Acta2 expression was decreased ( P < 0.005) and Ednrb was increased ( P < 0.05). In conclusion, nephrotoxic nephritis and hypercholesterolaemia led to decreased GLP1R specific immunohistochemical signal. Ex vivo vascular injury in the organ culture model leads to a decrease in expression of GLP1R expressionand contractile VSMC specific markers and increase in expression of dedifferentiation markers suggestive of an inverse relationship between phenotypic switch of the VSMC and the expression of the GLP1R; however, the causal relationship remains elusive.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While these antiinflammatory effects have not been attributed to GLP-1 action in specific organs or cell types, the kidney GLP-1R has been localized primarily to vascular smooth muscle cells within renal arteries and arterioles using either 125I-labeled exendin-4, a validated anti–GLP-1R antibody, or in situ hybridization (71, 72).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [72]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 1×
“GLP-1 is a gut derived peptide hormone released upon a carbohydrate rich meal to the blood stream where it is rapidly broken down by dipeptidyl peptidase IV resulting in a half-life in plasma of approximately 2 min (Holst 2007).”
BackgroundMotulsky, H. J., & Brown, R. E. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-123 · Cited by 1,616
Fate Tracing Reveals the Pericyte and Not Epithelial Origin of Myofibroblasts in Kidney Fibrosis
Humphreys, B. D., Lin, S.-L., Kobayashi, A., Hudson, T. E., Nowlin, B. T., Bonventre, J. V., Valerius, M. T., McMahon, A. P., & Duffield, J. S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090517 · Cited by 1,442
Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
The global burden of kidney disease and the sustainable development goals
Luyckx, V. A., Tonelli, M., & Stanifer, J. W. (2018) · Bulletin of the World Health Organization · doi:10.2471/blt.17.206441 · Cited by 926
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
Self-citationAcute kidney injury and chronic kidney disease: an integrated clinical syndrome
Chawla, L. S., & Kimmel, P. L. (2012) · Kidney International · doi:10.1038/ki.2012.208 · Cited by 829
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Inoguchi, T., Battan, R., Handler, E., Sportsman, J. R., Heath, W., & King, G. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.11059 · Cited by 740
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472
Effects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different?
Valdivielso, J. M., Rodríguez-Puyol, D., Pascual, J., Barrios, C., Bermúdez-López, M., Sánchez-Niño, M. D., Pérez-Fernández, M., & Ortiz, A. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312705 · Cited by 305
Basile, D. P., Friedrich, J. L., Spahic, J., Knipe, N., Mang, H., Leonard, E. C., Changizi-Ashtiyani, S., Bacallao, R. L., Molitoris, B. A., & Sutton, T. A. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00546.2010 · Cited by 296
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
Yu, M., Moreno, C., Hoagland, K. M., Dahly, A., Ditter, K., Mistry, M., & Roman, R. J. (2003) · Journal of Hypertension · doi:10.1097/00004872-200306000-00012 · Cited by 273
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
Hogan, A. E., Gaoatswe, G., Lynch, L., Corrigan, M. A., Woods, C., O’Connell, J., & O’Shea, D. (2014) · Diabetologia · doi:10.1007/s00125-013-3145-0 · Cited by 239
Skov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228 · cited 1×
“In healthy men it decreases angiotensin II secretion and aldosterone blood levels – components of the renin-angiotensin-aldosterone system, potentially indicating beneficial effects of GLP-1 on hypertension (Skov et al. 2013).”
BackgroundChoi, Y. (2000) · Human Pathology · doi:10.1053/hupa.2000.20373 · Cited by 204
Berk, B. C., Vallega, G., Muslin, A. J., Gordon, H. M., Canessa, M., & Alexander, R. W. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113964 · Cited by 192
Acute and chronic microvascular alterations in a mouse model of ischemic acute kidney injury
Hörbelt, M., Lee, S.-Y., Mang, H. E., Knipe, N. L., Sado, Y., Kribben, A., & Sutton, T. A. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00452.2006 · Cited by 171
Yuan, H., Li, X.-Z., Pitera, J. E., Long, D. A., & Woolf, A. S. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63586-9 · Cited by 159
Jensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141
Renal effects of glucagon-like peptide in rats
Moreno, C., Mistry, M., & Roman, R. J. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(01)01542-4 · Cited by 121
Parruti, G., Peracchia, F., Sallese, M., Ambrosini, G., Masini, M., Rotilio, D., & Blasi, A. D. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98412-7 · Cited by 116
Chronic kidney disease and vascular remodelling: molecular mechanisms and clinical implications
Briet, M. B., & Burns, K. D. (2012) · Clinical Science · doi:10.1042/cs20120074 · Cited by 115
Evaluation of medial hypertrophy in resistance vessels of spontaneously hypertensive rats.
Owens, G. K., Schwartz, S. M., & McCanna, M. E. (1988) · Hypertension · doi:10.1161/01.hyp.11.2.198 · Cited by 114
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 113
Ma, Y., Wang, W., Zhang, J., Lu, Y., Wu, W., Yan, H., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035835 · Cited by 111
Inscho, E. W., Imig, J. D., Cook, A. K., & Pollock, D. M. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706412 · Cited by 108 · cited 1×
“In rats, ETB receptors are expressed in kidney VSMCs of afferent arterioles mediating contraction and by endothelial cells of the efferent arteriole mediating vasodilatation, thus playing an important role in maintenance of vascular tone (Inscho et al. 2005).”
BackgroundAssociation Between Carotid Artery Intima-Media Thickness and Cardiovascular Risk Factors in CKD
Preston, E., Ellis, M. R., Kulinskaya, E., Davies, A. H., & Brown, E. A. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.07.048 · Cited by 102
Srivastava, R., Zhang, J., Go, G., Narayanan, A., Nottoli, T., & Mani, A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.09.028 · Cited by 76
Protein Kinase C β/Early Growth Response-1 Pathway
Yan, S., Harja, E., Andrassy, M., Fujita, T., & Schmidt, A. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.05.063 · Cited by 75
Digital image analysis improves precision of PD‐L1 scoring in cutaneous melanoma
Koelzer, V. H., Gisler, A., Hanhart, J. C., Griss, J., Wagner, S. N., Willi, N., Cathomas, G., Sachs, M., Kempf, W., Thommen, D. S., et al. (2018) · Histopathology · doi:10.1111/his.13528 · Cited by 71
PKCβ Promotes Vascular Inflammation and Acceleration of Atherosclerosis in Diabetic ApoE Null Mice
Kong, L., Shen, X., Lin, L., Leitges, M., Rosario, R., Zou, Y. S., & Yan, S. F. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.301113 · Cited by 69
The renal vascular response to diabetes
Carmines, P. K. (2010) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0b013e32833240fc · Cited by 68
Adner, M., Uddman, E., Cardell, L. O., & Edvinsson, L. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00206-x · Cited by 57
Mey, J. G. R. D., Uitendaal, M. P., Boonen, H. C. M., Vrijdag, M. J. J. F., Daemen, M. J. A. P., & Struijker-Boudier, H. A. J. (1989) · Circulation Research · doi:10.1161/01.res.65.4.1125 · Cited by 56
Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice
Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C. K., Rasmussen, S. E., Rolin, B., Nielsen, L. B., & Pedersen, T. X. (2016) · PLOS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47
Murine Nephrotoxic Nephritis as a Model of Chronic Kidney Disease
Ougaard, M. K., Kvist, P. H., Jensen, H. E., Hess, C., Rune, I., & Søndergaard, H. (2018) · International Journal of Nephrology · doi:10.1155/2018/8424502 · Cited by 47
Self-citationSrivastava, R., Rolyan, H., Xie, Y., Li, N., Bhat, N., Hong, L., Esteghamat, F., Adeniran, A., Geirsson, A., Zhang, J., et al. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311830 · Cited by 43
Ronn, J., Jensen, E. P., Wewer Albrechtsen, N. J., Holst, J. J., & Sorensen, C. M. (2017) · Physiological Reports · doi:10.14814/phy2.13503 · Cited by 40
Hays, T. T., Ma, B., Zhou, N., Stoll, S., Pearce, W. J., & Qiu, H. (2018) · Aging Cell · doi:10.1111/acel.12748 · Cited by 40
Foote, C. A., Castorena-Gonzalez, J. A., Ramirez-Perez, F. I., Jia, G., Hill, M. A., Reyes-Aldasoro, C. C., Sowers, J. R., & Martinez-Lemus, L. A. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00285 · Cited by 38
Katsurada, K., Nandi, S. S., Sharma, N. M., Zheng, H., Liu, X., & Patel, K. P. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00028.2019 · Cited by 37
Acute Renal Failure of Nosocomial Origin
Alscher, M. D., Erley, C. M. M., & Kuhlmann, M. K. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0149 · Cited by 29
Nitric oxide and vascular remodeling: Spotlight on the kidney
Eberhardt, W., & Pfeilschifter, J. M. (2007) · Kidney International · doi:10.1038/sj.ki.5002381 · Cited by 28
Jensen, E. P., Møller, S., Hviid, A. V., Veedfald, S., Holst, J. J., Pedersen, J., Ørskov, C., & Sorensen, C. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00579.2019 · Cited by 27
Silver, P. J., Lepore, R. E., Cumiskey, W. R., Kiefer, D., & Harris, A. L. (1988) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(88)90680-8 · Cited by 25
Kimura, T., Obata, A., Shimoda, M., Okauchi, S., Hirukawa, H., Kohara, K., Kinoshita, T., Nogami, Y., Nakanishi, S., Mune, T., et al. (2017) · Diabetes and Vascular Disease Research · doi:10.1177/1479164117725898 · Cited by 24
Bjørnholm, K. D., Skovsted, G. F., Mitgaard‐Thomsen, A., Rakipovski, G., Tveden‐Nyborg, P., Lykkesfeldt, J., & Povlsen, G. K. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13486 · Cited by 24
Self-citationPriksz, D., Bombicz, M., Varga, B., Kurucz, A., Gesztelyi, R., Balla, J., Tóth, A., Papp, Z., Szilvássy, Z., & Juhász, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102882 · Cited by 20
Liraglutide Improves the Kidney Function in a Murine Model of Chronic Kidney Disease
Ougaard, M. E., Sembach, F. E., Jensen, H. E., Pyke, C., Knudsen, L. B., & Kvist, P. H. (2020) · Nephron · doi:10.1159/000509418 · Cited by 19
Self-citationRapid functional upregulation of vasocontractile endothelin ETB receptors in rat coronary arteries
Skovsted, G. F., Pedersen, A. F., Larsen, R., Sheykhzade, M., & Edvinsson, L. I. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.02.009 · Cited by 19
Self-citationPeng, Z., Dang, A., & Arendshorst, W. J. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2006.06.009 · Cited by 18
Liu, L., Liu, J., Gao, Y., Ng, C., Yu, X., Dou, D., & Huang, Y. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000480 · Cited by 14
Krawczyk, K. K., Skovsted, G. F., Matic, L. P., Dreier, R., Berg, J. O., Hedin, U., Rippe, C., & Swärd, K. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00170.2018 · Cited by 14
Self-citationOugaard, M. K., Jensen, H. E., Thuen, I. D., Petersen, E., & Kvist, P. H. (2018) · Renal Failure · doi:10.1080/0886022x.2018.1533867 · Cited by 11
Self-citationVascular dysfunction and atherosclerosis in chronic kidney disease; A distinct entity
Silva, E. H., Wickramatilake, C. M., Lekamwasam, S., Mudduwa, L. K. B., & Ubayasiri, R. A. (2019) · Journal of Nephropathology · doi:10.15171/jnp.2019.17 · Cited by 5
Skovsted, G. F., Tveden‐Nyborg, P., & Lykkesfeldt, J. (2019) · Placenta · doi:10.1016/j.placenta.2019.01.015 · Cited by 3
Self-citation
Cited by
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Glucagon-like peptide-1 (GLP-1) is an endogenous incretin secreted by small intestinal L cells, consisting of two bioactive isoforms: GLP-1 (7-37) and GLP-1 (736).”
BackgroundResultAntiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“Interestingly, in colonic mucosal biopsies from individuals with inflammatory bowel disease, these genes were upregulated in inflamed tissue compared with noninflamed mucosa from the same patients, while GLP1R expression was downregulated.”
Reagents and models for detecting endogenous GLP1R and GIPR
Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40
GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells
Shilleh, A. H., Viloria, K., Broichhagen, J., Campbell, J. E., & Hodson, D. J. (2024) · Peptides · doi:10.1016/j.peptides.2024.171179 · Cited by 39
Localized GLP1 receptor pre-internalization directs pancreatic alpha cell to beta cell communication
Tong, J. C. L., Frazer-Morris, C., Shilleh, A. H., Viloria, K., de Bray, A., Nair, A. M., Johnson, P., Spiers, R. M., Kobiita, A., Olaniru, O. E., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.06.009 · Cited by 25
Metadata
- Authors
- Bjørnholm, K. D., Povlsen, G. K., Ougaard, M. E., Pyke, C., Rakipovski, G., Tveden-Nyborg, P., Lykkesfeldt, J., & Skovsted, G. F.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk (Denmark) (DK)
- 1Section of Experimental Animal Models, Department of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2021-03
- Volume
- 248
- Issue
- 3
- Pages
- 289-301
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W3120592517
- Cited by
- 10
- References
- 65
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2022: 2 · 2021: 2
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Keywords
- GLP-1 receptor, renal vasculature, nephrotoxic nephritis, vascular smooth muscle cell dedifferentiation, liraglutide, hypercholesterolemia, Ldlr knockout mice, Western diet, atherosclerosis, ACTA2, endothelin B receptor, renal hypertension
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Female, Nephritis, Organ Culture Techniques, Renal Artery, Vascular Diseases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.